BrightPath Biotherapeutics Co (TSE:4594) Cyclically Adjusted Revenue per Share: 円0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4594 BrightPath Biotherapeutics Co Ltd TSE:4594
35 GF Score
Price 円52.00
! 3 Warning Signs
View Full Analysis

What is BrightPath Biotherapeutics Co Cyclically Adjusted Revenue per Share?

BrightPath Biotherapeutics Co TSE:4594 +1.96% 35 Cyclically Adjusted Revenue per Share is 円0.00 as of Mar. 2026. GuruFocus rates TSE:4594 with a GF Score™ of 35/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

BrightPath Biotherapeutics Co's adjusted revenue per share for the three months ended in Mar. 2026 was 円0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-17), BrightPath Biotherapeutics Co's current stock price is 円52.00. BrightPath Biotherapeutics Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was 円0.00. BrightPath Biotherapeutics Co's Cyclically Adjusted PS Ratio of today is .


BrightPath Biotherapeutics Co  (TSE:4594) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


BrightPath Biotherapeutics Co Cyclically Adjusted Revenue per Share Related Terms


BrightPath Biotherapeutics Co Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for BrightPath Biotherapeutics Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BrightPath Biotherapeutics Co Cyclically Adjusted Revenue per Share Chart

BrightPath Biotherapeutics Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BrightPath Biotherapeutics Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

TSE:4594 vs VRTX, REGN, RVMD: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BrightPath Biotherapeutics Co Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where BrightPath Biotherapeutics Co's Cyclically Adjusted PS Ratio falls into.


TSE:4594
35GF Score
BrightPath Biotherapeutics Co Ltd TSE:4594
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BrightPath Biotherapeutics Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, BrightPath Biotherapeutics Co's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0/112.7000*112.7000
=0.000

Current CPI (Mar. 2026) = 112.7000.

BrightPath Biotherapeutics Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201512 6.200 98.100 7.123
201603 6.585 97.900 7.580
201606 6.036 98.100 6.934
201609 3.642 98.000 4.188
201612 3.270 98.400 3.745
201703 2.638 98.100 3.031
201706 2.435 98.500 2.786
201709 2.466 98.800 2.813
201712 1.701 99.400 1.929
201803 2.576 99.200 2.927
201806 2.918 99.200 3.315
201809 0.485 99.900 0.547
201812 0.290 99.700 0.328
201903 0.028 99.700 0.032
201906 0.020 99.800 0.023
201909 0.027 100.100 0.030
201912 0.020 100.500 0.022
202003 0.202 100.300 0.227
202006 0.007 99.900 0.008
202009 0.023 99.900 0.026
202012 0.009 99.300 0.010
202103 0.013 99.900 0.015
202106 0.004 99.500 0.005
202109 0.001 100.100 0.001
202112 0.001 100.100 0.001
202203 0.273 101.100 0.304
202206 0.002 101.800 0.002
202209 0.001 103.100 0.001
202212 0.080 104.100 0.087
202303 0.001 104.400 0.001
202306 0.000 105.200 0.000
202309 0.000 106.200 0.000
202312 0.000 106.800 0.000
202403 0.000 107.200 0.000
202406 0.000 108.200 0.000
202409 0.000 108.900 0.000
202503 0.000 111.100 0.000
202509 0.000 112.000 0.000
202512 0.000 113.000 0.000
202603 0.000 112.700 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of 円0.00 mean?
BrightPath Biotherapeutics Co (TSE:4594) has a Cyclically Adjusted Revenue per Share of 円0.00 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BrightPath Biotherapeutics Co and its competitors.
Is BrightPath Biotherapeutics Co's Cyclically Adjusted Revenue per Share too high?
BrightPath Biotherapeutics Co's current Cyclically Adjusted Revenue per Share is 円0.00. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Cyclically Adjusted Revenue per Share compare to VRTX and REGN?
BrightPath Biotherapeutics Co's Cyclically Adjusted Revenue per Share of 円0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on BrightPath Biotherapeutics Co and its competitors. BrightPath Biotherapeutics Co's current Cyclically Adjusted Revenue per Share is 円0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
BrightPath Biotherapeutics Co (TSE:4594) has a current Cyclically Adjusted Revenue per Share of 円0.00. The current Cyclically Adjusted Revenue per Share is 円0.00. BrightPath Biotherapeutics Co's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Cyclically Adjusted Revenue per Share is 円0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BrightPath Biotherapeutics Co Business Description

Address 2-2-4 Kojimachi, Kojimachi Central Building 7th Floor, Chiyoda-ku, Tokyo, JPN
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
35GF Score

Get the complete analysis for TSE:4594

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円52.00
Price